Skip to content

tDCS(Transcranial Direct Current Stimulation) Efficacy in Bipolar Depression : RCT Study

Augmentative Transcranial Direct Current Stimulation (tDCS) in Patients With Bipolar Depression: RCT, IIT Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03974815
Enrollment
64
Registered
2019-06-05
Start date
2019-06-25
Completion date
2020-10-30
Last updated
2019-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tDCS

Keywords

tDCS, Bipolar disorder, Depression

Brief summary

The purpose of this study is to determine whether transcranial direct current stimulation (tDCS) is effective and safe in the treatment Bipolar depression. Randomized, double-blind Controlled Clinical Trial. Subjects Adults (between 19 and 65 years of age) with Bipolar depression who meet the inclusion criteria and who agree to participate in the study Will recruit from clinical referrals. * Active tDCS Anode - left DLPFC Cathode - right DLPFC Electric current is 2mA - Current is applied for 30 min * Sham tDCS Same assembly is used Current is applied for 1 min Both groups 30\ 42 stimulation sessions on consecutive days. Baseline(visit 1), 2 week(visit 2), 4 week(visit 3), 6 week(visit 4), and 12 week(visit 5) Check compliance with mobile application(MINDD-CONNECT) connections.

Detailed description

Assessment: Depression rating scale: HAM-D(Hamiltion Depresiion Rating Scale), HAM-A(Hamilton Anxiety Rating Scale) Maniac rating scale: YMRS(Young Mania rating scale) CGI-BP(Clinical Global Impression-Bipolar) Q-LES-Q-SF(Quality of Life Enjoyment and Satisfaction Short form) Q-LES-Q-Q(Quality of Life Enjoyment and Satisfaction Questionnaire) qEEG(Quantitative Electroencephalography) Check compliance with mobile application(MINDD-CONNECT) connections.

Interventions

DEVICEACTIVE

We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials.

DEVICESHAM

We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials.

Sponsors

Ybrain Inc.
CollaboratorINDUSTRY
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Double blind

Intervention model description

Active stimulation group: 2mA, 30min (1min ramping up/down) Sham stimulation group: 0mA, 30min (1min ramping up/down)

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Type I or Type II of bipolar disorder meets the current major depression diagnostic criteria in DSM-5 * CGI Severity of lightness score ≥ 4 points * Taking mood stabilizers for at least four weeks before the day of screening

Exclusion criteria

* A history of clinically significant internal neurological disorders or head injury * mental retardation or cognitive impairment that will affect to make a consent form. * Patients at risk of suicide that may require hospitalization as determined by clinicians * A person who is determined to be excluded for using tDCS medical device for other reason (e.g. metal plate is inserted on head, etc.) * A person who is determined to have problems with scalp deformation, inflammatory response or brain wave and attachment of direct current because of other dermatological problem * A woman who disagree with medically allowed contraception\* until 24 weeks after the application of investigational device among woman subject who is possible to get pregnant \* Medically allowed contraception: condom, oral contraception for at least 3 month, injection or insert contraception, Intrauterine Device, etc. * pregnant woman or lactating woman * A person who is not suitable for this clinical trial based on principal investigator's determination other than above reasons

Design outcomes

Primary

MeasureTime frameDescription
Response rate of treatmentbaseline, 6weekResponse group: Reduce of HAM-D 50%
The changes in HAM-Dbaseline, 2week, 4week, 6weekThe changes in HAM-D(Hamilton Depression scale) will constitute the major research outcome measure. HAM-D17 * clinician-administered scale * assesses 17 items related to major depression (MD) * Individual items scored on 3 point (0 to 2) or 5 point scale (0 to 4) ; 0=absent, 4=most severe. * Total score: 0 to 66.

Secondary

MeasureTime frameDescription
YMRSbaseline, 2week, 4week, 6weekYoung Mania Rating Scale * Rating clinician-related or other trained rater * Main purpose to assess the severity of symptoms of manic * Population young adults and children * The scale consists of 11 items * Each item is scored on a scale of 0-8 or 0-4, with a total score range of 0-60 * The higher score, the worse it means.
Q-LES-Q-SFbaseline, 2week, 4week, 6weekQuality of Life Enjoyment and Satisfaction Questionnaire - Short Form
CGI-BPbaseline, 2week, 4week, 6weekClinical Global Impression- Bipolar
HAM-Abaseline, 2week, 4week, 6weekHamilton Anxiety Rating Scale * Rating clinician-related * Main purpose to assess the severity of symptoms of anxiety * Population adults, adolescents and children * The scale consists of 14 items * Each item is scored on a scale of 0-4, with a total score range of 0-56 * \<17: mild severity, 18-24: mild to moderate severity, 25-30: moderate to severe

Other

MeasureTime frameDescription
qEEGbaseline, 2weekThe changes of qEEG analysis

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026